MIAC AG

MIAC AG is a leading imaging CRO specializing in advanced imaging and medical expertise for international trials. Established in 1995 as an academic corporation of the Basel University Hospital, it has evolved into a key player in national and international research networks. MIAC's core focus is on translating novel imaging and post-processing modalities into applications in clinical trials, ensuring high impact scientific outcomes and personalized customer service. Within its Swiss quality standards, MIAC offers tailored data analysis pipelines, ensuring custom metrics and transparent, gapless data safety for imaging studies. The company's highly specialized team, comprising board-certified neuro-radiologists, physicists, biomedical engineers, IT specialists, technicians, and clinicians, delivers personalized image data analysis services and international trial support, catering specifically to leaders in the pharmaceutical industry. Notably, all of MIAC's services adhere to Swiss quality standards and comply with FDA – 21 CFR Part 11 & ICH – Good Clinical Practices, demonstrating their commitment to regulatory compliance and quality assurance. MIAC's expertise and dedication to advanced imaging make it a prominent player in the Health Care and Pharmaceutical industries, offering comprehensive support for international trials. With its strong academic foundation and integration into global research networks, the company stands well-positioned to continue driving innovation in medical image analysis. Overall, MIAC AG presents an opportunity for potential investors seeking exposure to the rapidly evolving field of medical imaging and clinical trial support. With its established track record and commitment to quality, the company may be an attractive prospect for venture capital firms seeking opportunities in the healthcare and pharmaceutical sectors.